Study suggests precision medicine for adrenal cancer

A new international study gives a glimmer of hope for personalizing treatment for one of the most rare and aggressive forms of cancer. In a randomized phase 3 trial, adrenal cancer patients receiving the investigational drug linsitinib fared no better than patients receiving a placebo. But the researchers noticed a small subset of patients who had significant response and remained on the drug for an extended time. “While it was only a small subset of patients who responded to linsitinib, this remains very promising in the era of precision medicine,” says co-principle investigator Gary D. Hammer, M.D., Ph.D., Millie Schembechler Professor of Adrenal Cancer at the University of Michigan Comprehensive Cancer Center. Read more here.